Free shipping on all orders over $ 500


Cat. No. M13622
Prexasertib Structure


Size Price Availability Quantity
5mg USD 127  USD127 In stock
25mg USD 395  USD395 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity.

Chemical Information
Molecular Weight 365.39
Formula C18H19N7O2
CAS Number 1234015-52-1
Form Solid
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Jason Ostergaard, et al. Br J Haematol. Preclinical efficacy of prexasertib in acute lymphoblastic leukemia

[2] Chenguang Liu, et al. Nat Chem. Automated synthesis of prexasertib and derivatives enabled by continuous-flow solid-phase synthesis

[3] Giulio Evangelisti, et al. Expert Opin Investig Drugs. Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer

[4] Yoshihito Morimoto, et al. Oncol Rep. Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1

[5] Gesuino Angius, et al. Cancer Chemother Pharmacol. Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development

Related Checkpoint Products

Chk2-IN-1 (compound 1) is a potent and selective inhibitor of checkpoint kinase 2 (Chk2), with IC50s of 13.5 nM and 220.4 nM for Chk2 and Chk1, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM)-dependent Chk2-mediated radioprotection effect.


MU380 is a potent and selective CHK1 inhibitor that induces apoptosis and has anticancer activity.


GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignancies.


GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC50s of 0.0011, 1.5 µM for ChKl, ChK2, respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis. gemcitabine and GNE-900 administration shows anti-tumor activity.

GDC0575 hydrochloride

GDC0575 (ARRY-575) hydrochloride is a highly-selective and orally active Chk1 (IC50=1.2 nM) inhibitor. GDC0575 (ARRY-575) hydrochloride can be used for colitis-associated cancer (CAC) and colitis research.

Abmole Inhibitor Catalog

Keywords: Prexasertib, LY2606368 supplier, Checkpoint, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.